After BTIG and Cowen & Co. gave Voyager Therapeutics Inc (NASDAQ: VYGR) a Buy rating last month, the company received another Buy, this time from Canaccord Genuity. Analyst Sumant Kulkarni maintained a Buy rating on Voyager Therapeutics Inc today and set a price target of $35. The company’s shares opened today at $21.41.
According to TipRanks.com, Kulkarni is a 3-star analyst with an average return of 3.8% and a 50.7% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Intra-Cellular Therapies, and Alder Biopharmaceuticals.
Currently, the analyst consensus on Voyager Therapeutics Inc is Strong Buy and the average price target is $34.71, representing a 62.1% upside.
In a report issued on June 4, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $19.93 million. In comparison, last year the company had a GAAP net loss of $16.65 million.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
